tetano
Editor, Senior Moderator
Biotechnol Lett
. 2022 Jan 19.
doi: 10.1007/s10529-021-03209-8. Online ahead of print.
Stem cells or their exosomes: which is preferred in COVID-19 treatment?
Nashmin Fayazi Hosseini[SUP] 1 [/SUP], Razieh Dalirfardouei[SUP] 1 2 [/SUP], Mohammad Reza Aliramaei[SUP] 3 [/SUP], Rezvan Najafi[SUP] 4 [/SUP]
Affiliations
Abstract
It only took 8 months for the pneumonia caused by a previously unknown coronavirus to turn into a global pandemic of unprecedentedly far-reaching implications. Failure of the already discovered treatment measures opened up a new opportunity to evaluate the potentials of mesenchymal stem cells and their extracellular vesicles (EVs), exosomes in particular. Eventually, the initial success experienced after the use of MSCs in treating the new pneumonia by Lnge and his team backed up the idea of MSC-based therapies and pushed them closer to becoming a reality. However, MSC-related concerns regarding safety such as abnormal differentiation, spontaneous malignant and the formation of ectopic tissues have triggered the replacement of MSCs by their secreted exosomes. The issue has been further strengthened by the fact that the exosomes leave similar treatment impacts when compared to their parental cells. In recent years, much attention has been paid to the use of MSC-derived exosomes in the treatment of a variety of diseases. With a primary focus on COVID-19 and its current treatment methods, the present review looks into the potentials of MSCs and MSC-derived exosomes in battling the ongoing pandemic. Finally, the research will draw an analogy between exosomes and their parental cells, when it comes to the progresses and challenges in using exosomes as a large-scale treatment method.
Keywords: COVID-19; Coronavirus; Exosome based therapy; Mesenchymal stem cell-derived exosomes.
. 2022 Jan 19.
doi: 10.1007/s10529-021-03209-8. Online ahead of print.
Stem cells or their exosomes: which is preferred in COVID-19 treatment?
Nashmin Fayazi Hosseini[SUP] 1 [/SUP], Razieh Dalirfardouei[SUP] 1 2 [/SUP], Mohammad Reza Aliramaei[SUP] 3 [/SUP], Rezvan Najafi[SUP] 4 [/SUP]
Affiliations
- PMID: 35043287
- DOI: 10.1007/s10529-021-03209-8
Abstract
It only took 8 months for the pneumonia caused by a previously unknown coronavirus to turn into a global pandemic of unprecedentedly far-reaching implications. Failure of the already discovered treatment measures opened up a new opportunity to evaluate the potentials of mesenchymal stem cells and their extracellular vesicles (EVs), exosomes in particular. Eventually, the initial success experienced after the use of MSCs in treating the new pneumonia by Lnge and his team backed up the idea of MSC-based therapies and pushed them closer to becoming a reality. However, MSC-related concerns regarding safety such as abnormal differentiation, spontaneous malignant and the formation of ectopic tissues have triggered the replacement of MSCs by their secreted exosomes. The issue has been further strengthened by the fact that the exosomes leave similar treatment impacts when compared to their parental cells. In recent years, much attention has been paid to the use of MSC-derived exosomes in the treatment of a variety of diseases. With a primary focus on COVID-19 and its current treatment methods, the present review looks into the potentials of MSCs and MSC-derived exosomes in battling the ongoing pandemic. Finally, the research will draw an analogy between exosomes and their parental cells, when it comes to the progresses and challenges in using exosomes as a large-scale treatment method.
Keywords: COVID-19; Coronavirus; Exosome based therapy; Mesenchymal stem cell-derived exosomes.